3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
Nivolumab
26
pembrolizumab
25
Specimen Handling
18
Ipilimumab
17
Magnetic Resonance Spectroscopy
12
Opdualag
7
CTLA-4 Antigen
7
Biopsy
6
trametinib
5
relatlimab
5
binimetinib
5
dabrafenib
4
Paclitaxel
4
Cyclophosphamide
4
fludarabine
3
capivasertib
3
atezolizumab
3
aldesleukin
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
tislelizumab
2
sargramostim
2
omipalisib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled